CLOV

Clover is a Medicare Advantage insurer with a genuine growth story: FY2025 revenue rose 40.3% to $1.92B, membership grew to 113,803 (and the company entered 2026 with over 153,000 members after a 53% AEP jump), all on a debt-free balance sheet with $309M of equity. At a $2.72B market cap that's ~1.4x sales — not demanding for that growth rate if the unit economics were improving. The problem is they aren't. The single most important metric for an MA plan is the medical loss ratio, and the MD&A shows the Insurance benefits expense ratio deteriorated sharply from 81.2% to 90.9% (normalized 91.5%), meaning far more of every premium dollar went to claims. That flowed straight through the P&L: Adjusted EBITDA collapsed from $70.1M to $21.7M, net loss widened to -$85.5M from -$43.0M, and gross margin sits at just 13.4%. So the company is growing revenue by adding members while the profitability of each member got materially worse — the opposite of the trajectory it showed from 2021 to 2024.

The forward picture has a concrete overhang the filing flags directly: on October 9, 2025 CMS cut the PPO plan's Star rating to 3.5 for rating year 2026, affecting payment year 2027 — and over 97% of members are in that PPO. Lower Stars means lower CMS quality-bonus payments and rebate dollars right as the company scales membership, which pressures both revenue and the already-stretched benefits ratio. Cash is the other yellow flag: cash and equivalents fell 59.8% to $78.3M and operating cash flow swung to -$66.9M, while the 10-K itself warns it may need additional, potentially dilutive financing. Share count is already creeping up (+4.5%) and the accumulated deficit stands at $2.29B.